Preliminary program:

Day 1 - Wednesday 18. May

Registration and welcome
07:00 -
Registration

08:30 - 09:00
Opening and welcome
Enrico Mihich,
Hans-Peter Huber,
Anne-Lise Børresen-Dale
09:00 - 09:45
Opening keynote on P4 and cancer
Leroy Hood

Session I: Genetic Profiling of Patients, Prediction of Risk and therapy response
09:45 - 10:15
Gene network approaches to understanding polygenic risk
Bruce Ponder
Cancer Research Institute
Cambridge, UK
10:15 - 10:25
Discussion

10:25 - 10:45
Coffee break

10:45 - 11:15
Germline genetic variation and ovarian cancer risk: the clinical significance
Paul Pharoah
Strangeways Research Laboratory
Cambridge, UK
11:15 - 11:25
Discussion

11:25 - 11:40 Short poster presentation, selected from abstracts

Session II: Molecular Profiling of Tumors and Metastases
11:40 - 12:10
Genome-guided Precision Cancer Medicine
Elaine Mardis
The Genome Inst., Washington Univ
St. Louis, Missouri, USA
12:10 - 12:20
Discussion

12:20 - 12:35
Short poster presentation, selected from abstracts

12:35 - 14:00
Lunch, poster viewing, and exhibition
14:00 - 14:30
Genome scale molecular profiling provides a robust way to identify and qualify key biological processes driving cancer with the potential to personalize cancer treatment
Zoltan Szallasi
Technical University of Denmark
14:30 - 14:40
Discussion
14:40 - 15:10
Genomic-driver based stratification of breast cancer
Carlos Caldas
Cancer Research Institute
Cambridge UK
15:10 - 15:20
Discussion

15:20 - 15:35
Short poster presentation, selected from abstracts

15:35 - 16:00
Coffee break

16:00 - 16:30
Molecular Archaeology of Cancer
Peter van Loo
Crick Center
London, UK
16:30 - 16:40
Discussion

16:40 - 17:10
Genomic Analysis of Breast Tumors and Biomarkers of Therapeutic Responsiveness
Charles M. Perou
UNC - Chapel Hill
North Carolina, USA
17:10 - 17:20
Discussion

17:20 - 18:30
Poster viewing and exhibition

19:30 -  Social event



Day 2 - Thursday 19. May
Session III: Tumor-host Microenvironment Interaction and Metabolism
08:30 - 09:00
The evolution of p53 inherited mutant tumors
Arnold Levine
Princeton University
USA
09:00 - 09:10
Discussion

09:10 - 09:40
Unraveling clinical enigmas: Implications of cancer cell mobility and tissue geometry
Larry Norton
Memorial Sloan-Kettering Cancer Center
New York, USA.
09:40 - 09:50
Discussion

09:50 - 10:05
Coffee break

10:05 - 10:35
All pathways integrate to make you, you: Even glucose metabolism!
Mina Bissell
Lawrence Berkeley National Laboratory
California, USA
10:35 - 10:45
Discussion

10:45 - 11:15
Deconvolution of the triple-negative breast cancer microenvironment
Morag Park
McGill University
Montreal, Canada
11:15 - 11:25
Discussion

11:25 - 11:40
Short poster presentation, selected from abstracts


Session IV: Targeted Therapy
11:40 - 12:10
Overcoming challenges to the delivery of personalized medicine
Gordon Mills
MD Anderson Cancer Center
Houston, Texas, USA
12:10 - 12:20
Discussion

12:20 - 13:50
Lunch, poster viewing, and exhibition

13:50 - 14:20
Synthetic lethal drug combinations for the treatment of cancer
Rene Bernards
The Netherlands Cancer Institute
Netherlands
14:20 - 14:30
Discussion

14:30 - 15:00
Understanding and managing breast cancer as a complex adaptive system
Joe Gray
Knight Cancer Inst, Oregon Health & Sci Univ
Oregon, USA
15:00 - 15:10
Discussion

15:10 - 15:40
Heterogeneity, drug resistance and clonal evolution in colorectal cancer
Alberto Bardelli
University of Torino
Italy
15:40 - 15:50
Discussion

15:50 - 16:05
Coffee break

16:05 - 16:35
Intracellular antigens as a source of targets of antibody-based immunotherapy for the treatment of
Soldano Ferrone
Massachusetts General Hospital, Harvard
Boston, USA
16:35 - 16:45
Discussion

16:45 - 17:00
Short poster presentation, selected from abstracts

18:00 -  Social event



Day 3 - Friday 20. May
Session V: Translation
08:30 - 09:00
Applying molecular profiling in cancer
Christof von Kalle
German Cancer Research Center (DKFZ)
Germany
09:00 - 09:10
Discussion

09:10 - 09:40
Biomarker indication for increased likelihood of therapeutic response
Laura van't Veer
University of California
San Francisco, USA
09:40 - 09:50
Discussion

09:50 - 10:05
Coffee break

10:05 - 10:35
Translation biology into therapeutics; clinical beacons mapping the terrain
Per Eystein Lønning
University of Bergen
Norway
10:35 - 10:45
Discussion

10:45 - 11:15
Breast tumor heterogeneity: A challenge for translation
Anne-Lise Børresen-Dale
Oslo University Hospital
Norway
11:15 - 11:25
Discussion


Session VI: The impact of social and ethical issues on personalized medicine
11:25 - 11:50
Social and ethical perspectives
Serena Nik-Zainal
Sanger Center
Hinxton, Cambridge, UK
11:50 - 12:00
Discussion


Summary and highlights:
Kurt Zänker, Institute for Immunology, Univ. Witten, and The Fritz Bender Foundation, Germany
_